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e.2013.04Abstract Background: Pulmonary arterial hypertension (PAH) is a disabling chronic disorder of
the pulmonary vasculature, which is characterized by increased pulmonary artery pressure (PAP) as
a result of increased pulmonary vascular resistance (PVR). The most accepted hemodynamic deﬁ-
nition of PH is a mean PAP >25 mmHg. It is accidentally discovered preoperatively through per-
forming an echocardiogram in patients suspected of having PH, as these patients suffer from
dyspnea which is the most frequently presenting symptom. Additional symptoms include fatigue,
weakness, angina, syncope, and lower limb edema. The aim of the study was to evaluate the efﬁcacy
and safety of preoperative oral sildenaﬁl administration in the management of pulmonary hyperten-
sive patients scheduled for non-cardiac surgery.
Patients and methods: 30 Patients, (ASA II–III), suffering from pulmonary hypertension and
scheduled for non-cardiac surgery were randomly assigned to one of two groups. Group I received
25 mg sildenaﬁl twice daily for one week before surgery. Group II received placebo in the same way.
PAP, LVEF and RVEF (through echocardiogram), heart rate, mean arterial blood pressure, SpO2
(oxygen saturation), functional class and 6-min walk distance were measured and recorded at base-
line and one week after treatment in both groups.
Results: Sildenaﬁl signiﬁcantly reduced PAP and improved exercise tolerance, functional class, 6-
min walk distance and SpO2 without signiﬁcant alteration of heart rate and mean arterial blood
pressure.
Conclusion: The study showed effective and safe administration of preoperative oral sildenaﬁl in
the management of pulmonary hypertensive patients scheduled for non-cardiac surgery.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.333357.
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Pulmonary arterial hypertension (PAH) is a syndrome charac-
terized by symptoms of dyspnea, fatigue, chest pain, and syn-
cope. Underlying mechanisms are a progressive increase of
pulmonary vascular resistance and a sustained elevation of
pulmonary arterial pressure to more than 25 mmHg at rest.1
It may lead to a decreased functional capacity, and rightand hosting by Elsevier B.V. All rights reserved.
Table 1 Baseline demographic data.
Group I Group II
Number 15 15
Age (years) 49.93 ± 10.12 49.6 ± 10.15
Sex (female/male) 3/12 4/11
Weight (kgs) 84.0 ± 7.12 82.93 ± 6.94
Height (cm) 172.6 ± 4.15 171 ± 4.33
NYHA class
I 2 2
II 7 8
III 6 5
Group I: sildenaﬁl, Group II: placebo, NYHA: New-york Heart
Association, Data are expressed as number of patients and
mean ± SD.
Table 2 NYHA class in 2 groups.
Group I Group II
Baseline Week 1 Baseline Week 1
I 2 7 2 3
II 7 7 8 7
III 6 1 5 5
P value 0.042* 0.875
Group I: sildenaﬁl, Group II: placebo. Data are presented as
number of patients.
* P< 0.05 signiﬁcant between two groups.
14 A.M. Eskandarventricular failure, and is often associated with early death.2,3
PAH can be classiﬁed into ﬁve main categories according to
the updated clinical classiﬁcation of PAH.1 Sildenaﬁl is a selec-
tive inhibitor of type 5 phosphodiesterase (PDE), the predom-
inant PDE isoform responsible for hydrolysis of intracellular
cyclic guanosine monophosphate (cGMP), in the pulmonary
vasculature.4 Many studies were done on the effect of sildenaﬁl
on pulmonary hypertension, but no research has been done on
its use in the preoperative management of patients with pul-
monary hypertension. The aim of the study was to evaluate
the efﬁcacy and safety of sildenaﬁl in the preoperative prepara-
tion of pulmonary hypertension patients scheduled for non-
cardiac surgery.
2. Patients and methods
The protocol was approved by the faculty of medicine, Meno-
uﬁya university medical ethics committee and patients gave
written informed consent. Thirty patients of both sex and aged
20–60 years admitted during 1 year period to Menouﬁya Uni-
versity Hospitals with ASA physical status I–III and pulmon-
ary hypertension scheduled for non-cardiac surgery, were
allocated to one of two parallel groups (control, n= 15 and
sildenaﬁl, n= 15). Exclusion criteria included patients with
class IV PAH, hemodynamic instability, patients taking ni-
trates and known allergy to the study drug.
The sildenaﬁl group (group I) received 25 mg of oral silde-
naﬁl twice daily and the control group (group II) received pla-
cebo for 1 week during hospital admission. Before starting
treatment baseline assessment of all patients was done includ-
ing heart rate mean arterial blood pressure, SpO2, 6-minute
walk distance, exercise tolerance (assessed through NYHA
class)5 and echocardiography to show PAP, LVED, EF. Also
visual abnormalities (blurred vision or color vision abnormal-
ities), liver enzymes and creatinine levels were recorded. These
parameters were also measured and recorded one week after
treatment. To determine the efﬁcacy of sildenaﬁl for the ad-
vanced treatment of PAH various endpoints have been inves-
tigated. Some were invasive and others were less invasive
endpoints as the World Health Organization (WHO) func-
tional class and the total distance walked in 6 min (6MWD)
were also used to examine treatment efﬁcacy.6 The use of the
World Health Organization modiﬁed functional classiﬁcation
(FC) scale allows for standardized grading.7 The functional
class ranges from class I representing PAH without limitation
of physical activity to class IV meaning PAH with inability to
carry out any physical activity without symptoms. The six-
minute walking distance (6MWD) is an exercise test with out-
come in meters. Beneﬁt of the 6MWD is the simplicity, and the
ease of its application.8 The validity of the 6MWD is question-
able in patients with an intellectual disability.9,10
Statistical analysis was performed using Student’s t-test for
quantitative data which are expressed as mean ± SD and chi-
squared test for categorical data which are presented as num-
ber of patients (n). P< 0.05 was considered statistically
signiﬁcant.
3. Results
Thirty patients, presented with pulmonary hypertension, ASA
physical status II–III and scheduled for non-cardiac surgeryparticipated in the present study. They were classiﬁed into
two equal groups (sildenaﬁl, n= 15 and placebo, n= 15).
The groups were comparable with respect to age, sex, weight
and height (Table 1).
There was a non signiﬁcant decrease in heart rate and mean
arterial blood pressure in the sildenaﬁl group more than the
placebo group and between the basal measurement and after
1 week of treatment in the sildenaﬁl group. In the sildenaﬁl
group, nine patients of NYHA class II–III showed improve-
ment in functional class (from class III, 4 patients improved
to class II and one improved to class I plus 4 improved from
class II to class I). Overall 9/15 patients (60%) demonstrated
improvement in overall health and well-being, with a signiﬁ-
cant difference (P= 0.042) after 1 week of treatment with sil-
denaﬁl, while group II showed only improvement of 1 patient
from NYHA class II to class I (1/15, 6.66%) (Table 2).
Improvement was also noted in physical activity and patients
reported that by the end of the study they were able to climb
stairs and walk longer distances. This was approved by a sig-
niﬁcant increase in the 6-minute walk distance test (from
294.4 ± 12.36 to 305.73 ± 13.06 m, P= 0.021) between base-
line and 1 week after treatment (Table 3) and a signiﬁcant dif-
ference (P< 0.001) between the two groups (Table 5). Also,
there was a signiﬁcant decrease in mean PAP (from
49.47 ± 15.72 at baseline to 38.67 ± 10.81, P= 0.037) (Table
3) and between the two groups (from 48.93 ± 14.04 in the pla-
cebo group to 38.67 ± 10.81 in the sildenaﬁl group,
P= 0.033) (Tables 4 and 5) as detected through transthoracic
echocardiography. There was a non signiﬁcant improvement
of right and left ventricular functions which could be detected
by the improvement of FS and EF after sildenaﬁl treatment in
Table 3 Hemodynamic, 6-min walk spo2 values before and
after sildenaﬁl administration (Group I).
Base line Week 1 P value
Heart rate 81.13 ± 6.8 77.53 ± 4.61 0.1
MAP 97.27 ± 7.31 91.8 ± 8.08 0.06
PAP 49.47 ± 15.72 38.67 ± 10.81* 0.037
EF 53.87 ± 4.49 54.4 ± 3.85 0.731
FS 29.53 ± 4.03 30.27 ± 3.53 0.597
6-min walk 294.4 ± 12.36 305.73 ± 13.06* 0.021
SpO2 92.53 ± 1.6 94.2 ± 1.21
* 0.003
Data are presented as mean ± SD.
* P< 0.05 signiﬁcant between two groups.
Table 6 Clinical and laboratory adverse effects.
Sildenaﬁl Placebo
Bleeding 0 0
Arrhythmia 1 1
Syncope 0 0
Headache 7* 1
Flushing 2 1
Visual dist. 0 0
›liver enzyes 0 0
›creatinine 0 0
Data are presented as number of patients.
* P< 0.05 signiﬁcant between two groups.
Table 4 Hemodynamic, 6-min walk SpO2 values before and
after placebo administration (Group II).
Base line Week 1 P value
Heart rate 80.07 ± 5.99 79.6 ± 6.3 0.836
MAP 97.87 ± 9.04 96 ± 10.35 0.06
PAP 48.73 ± 15.94 48.93 ± 14.04 0.971
EF 51.8 ± 3.75 51.8 ± 3.65 1.00
FS 29.93 ± 3.92 30.0 ± 3.91 0.961
6-min walk 289 ± 10.44 289.6 ± 9.47 0.87
SpO2 93.13 ± 1.41 93.27 ± 1.22 0.773
Data are presented as mean ± SD.
Table 5 One week characterstics of study subjects.
Sildenaﬁl Placebo P value
Heart rate 77.53 ± 4.61 79.6 ± 6.3 0.313
MAP 91.8 ± 8.08 96 ± 10.35 0.226
PAP 38.67 ± 10.81 48.93 ± 14.04* 0.033
EF 54.4 ± 3.85 51.8 ± 3.65 0.068
FS 30.27 ± 3.53 30.0 ± 3.91 0.844
6-min walk 305.73 ± 13.06 289.6 ± 9.47 <0.001
SpO2 94.2 ± 1.21 93.27 ± 1.22* 0.045
Data are presented as mean ± SD.
* P< 0.05 signiﬁcant.
 P< 0.001 highly signiﬁcant between two groups.
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(Tables 4 and 5). There was a signiﬁcant increase in SpO2
(from 92.53 ± 1.6 at baseline to 94.2 ± 1.21, after sildinaﬁl
treatment P= 0.003) (Table 3) and in between the two groups
(from 93.27 ± 1.22 in the placebo group to 94.2 ± 1.21 in the
sildenaﬁl group, P= 0.045) (Tables 4 and 5). There were no
signiﬁcant hemodynamic or other clinical and laboratory ad-
verse effects between the two groups except for headache
which increased signiﬁcantly in the sildenaﬁl group (Table 6).
4. Discussion
This study evaluated sildenaﬁl as a preoperative treatment of
PAH. Administration of oral sildenaﬁl (25 mg twice daily)
for 1 week was safe and led to improvement of functional class,
exercise capacity and hemodynamics with no systemic side
effects.The present study showed a selective pulmonary vasodila-
tion effect of sildenaﬁl which was approved by the signiﬁcant
decrease of PAP, as sildenaﬁl is a speciﬁc phosphodiestrase-5
inhibitor with acute and chronic hemodynamic effects in pa-
tients with pulmonary hypertension.11,12 PDE-5 is an enzyme
present in the lung and penile tissue which causes hydrolysis
of c-GMP to inactive compounds.13 Inhibition of PDE-5 by
PDE-5 inhibitors as sildenaﬁl increases c-GMP concentrations,
which promotes vasodilatation.14
The study also showed a signiﬁcant increase in exercise tol-
erance and 6-minute walk distance which occurred as a result
of improvement of pulmonary hemodynamics and right ven-
tricular function evidenced by an increase of RVEF.15 Also in-
crease cardic output is another cause reported by studies done
by Gregory and others16 who showed the improvement of
exercise hemodynamics and oxygen uptake in patients with
systolic heart failure after sildenaﬁl treatment and Sastry and
others17 who studied the clinical efﬁcacy of sildenaﬁl in pri-
mary pulmonary hypertension. These observations are consis-
tent with those of Sastry and colleagues,17 Singh and
colleagues18 who found that sildenaﬁl signiﬁcantly improves
the symptomatic status exercise capacity, NYHA class and
hemodynamic parameters of patients with severe pulmonary
artery hypertension, and Galie and colleagues19 who reported
improvement of exercise capacity, WHO functional class, and
hemodynamics in patients with symptomatic pulmonary arte-
rial hypertension. Furthermore, there was a signiﬁcant increase
in systemic oxygen saturations. A study done by Ghofrani and
others20 in patients with severe lung ﬁbrosis and secondary
pulmonary hypertension demonstrated that sildenaﬁl acts as
a selective pulmonary vasodilator and led to improved gas ex-
change by recruiting selectively well-ventilated areas of the
lung. We did not speciﬁcally measure gas exchange in our pa-
tients. Hence, it remains unclear whether the increased oxygen
saturations observed in the present study due to improved lung
ventilation/perfusion matching, improved CO, and a reduction
in right-to-left cardiac shunting either separately or in combi-
nation, these observations were matched with a study done by
Mikhail and colleagues21 who studied the acute and mid-term
clinical and hemodynamic effects of sildenaﬁl in pulmonary
hypertension.
Adverse events as elevated liver enzymes, increased creati-
nine concentration, prolonged bleeding time and clinical side
effects (visual disturbances, arrhythmia) did not differ between
sildenaﬁl and the placebo groups except for headache which
occurred more in the sildenaﬁl group 7/15 (46.7%) than in
16 A.M. Eskandarthe placebo group 1/15 (6.7%, P= 0.039). These observations
documented the safe use of sildenaﬁl in preoperative manage-
ment as found by studies done by Michelakis and colleagues15
and Gregory and others.16
In conclusion, the present study showed, one week of pre-
operative treatment with oral PDE-5 inhibitor sildenaﬁl is a
new and safe approach to achieve selective pulmonary vasodi-
latation in patients scheduled for non-cardiac surgery. As sil-
denaﬁl in this study decreased PAP, improved exercise
tolerance, functional class, 6-min walk distance, oxygen satu-
ration and RVF with insigniﬁcant side effects.
Conﬂict of interest
None declared.
References
1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix
CP, Denton CP, et al. Updated clinical classiﬁcation of pulmon-
ary hypertension. J Am Coll Cardiol 2009;54(Suppl. 1):S43–54.
2. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S,
Rizzoli G, et al. Eisenmenger syndrome. Factors relating to
deterioration and death. Eur Heart J 1998;19(12):1845–55.
3. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl
J Med 2004;351(16):1655–65.
4. Mark JS, Jeroen CV, Marielle GD, Berto J, Barbara JM. Adult
patients with pulmonary arterial hypertension due to congenital
heart disease: a review on advanced medical treatment with
bosentan. Ther Clin Risk Manag 2010;6:359–66.
5. Stuart DR, Matthew AS, Jennifer LR, Myrvin HE, Stephen SG,
Eileen MH, et al. New York heart association functional class
predicts exercise parameters in the current era. Am Heart J 2009
October;158(Suppl. 4):S24–30.
6. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO,
Taylor DW, et al. The 6-minute walk: a new measure of exercise
capacity in patients with chronic heart failure. Can Med Assoc J
1985;132(8):919–23.
7. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ,
Olschewski H, et al. Diagnosis and differential assessment of
pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12
Suppl. S):S40–7.
8. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita
M, et al. Clinical correlates and prognostic signiﬁcance of six-
minute walk test in patients with primary pulmonary hyperten-
sion. Comparison with cardiopulmonary exercise testing. Am J
Respir Crit Care Med 2000;161(2 Pt 1):487–92.
9. Vis JC, Thoonsen H, Duffels MG, de Bruin-Bon RA, Husiman
AP, Van-Dijk AP, et al. Six-minute walk test in patients withDown syndrome: validity and reproducibility. Arch Phys Med
Rehabil 2009;90(8):1423–7.
10. Duffels MG, Vis JC, Van Loon RL, Nieuwkerk PT, Van Dijk AP,
Hoendermis ES, et al. Effect of bosentan on exercise capacity and
quality of life in adults with pulmonary arterial hypertension
associated with congenital heart disease with and without Down’s
syndrome. Am J Cardiol 2009;103(9):1309–15.
11. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD.
Immediate and long-term hemodynamic and clinical effects of
sildenaﬁl in patients with pulmonary arterial hypertension receiv-
ing vasodilator therapy. Mayo Clin Proc 2003;78:1207–13.
12. Michelakis E, Tymchak W, Noga M, Webster L, Wu Xc, Lien D,
et al. Oral sildenaﬁl is an effective and speciﬁc pulmonary
vasodilator in patients with pulmonary arterial hypertension:
comparison with inhaled nitricoxide. Circulation
2002;105:2398–403.
13. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5:
a strong basis for treating pulmonary hypertension with PDE5
inhibitors. Biochem Biophys Res Commun 2005;334:930–8.
14. Joe R, Anderson, James J. Nawarskas: pharmacotherapeutic
management of pulmonary arterial hypertension. Cardiol Rev
2010;18:148–62.
15. Michelakis ED, Tymchak W, Noga M, Weebster L, Wu XC, Lien
D, et al. Long-term treatment with oral sildenaﬁl is safe and
improves functional capacity and hemodynamics in patients with
pulmonary arterial hypertension. Circulation 2003;108:2066–9.
16. Gregory DL, Justine Lachmann, Janice Camuso, John JL, Jordan
E, Maryann E, et al. Sildenaﬁl improves exercise hemodynamics
and oxygen uptake in patients with systolic heart failure. Circu-
lation 2007;115:59–66.
17. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efﬁcacy
of sildenaﬁl in primary pulmonary hypertension: a randomized,
placebo-controlled, doubleblind, crossover study. J Am Coll
Cardiol 2004;43:1149–53.
18. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A
randomized, placebo-controlled, double-blind, crossover study to
evaluate the efﬁcacy of oral sildenaﬁl therapy in severe pulmonary
artery hypertension. Am Heart J 2006;151:851.
19. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch
D, et al. Sildenaﬁl use in pulmonary arterial hypertension
(SUPER) study group. Sildenaﬁl citrate therapy for pulmonary
arterial hypertension. N Engl J Med 2006;354:2400–1.
20. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski
N, Weissmann N, et al. Sildenaﬁl for the treatment of lung ﬁbrosis
and pulmonary hypertension: a randomised controlled trial.
Lancet 2002;360:895–900.
21. Mikhail GW, Prasad SK, Li W, Rogers P, Chester AH, Bayne S,
et al. Clinical and haemodynamic effects of sildenaﬁl in pulmon-
ary hypertension: acute and mid-term effects. Eur Heart J
2004;25(5):431–6.
